{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:43:32Z","timestamp":1787024612247,"version":"build-2736575974"},"reference-count":54,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The use of levetiracetam (LEV) has been increasing given its favorable pharmacokinetic profile. Numerous population pharmacokinetic studies for LEV have been conducted. However, there are some discrepancies regarding factors affecting its pharmacokinetic variability. Therefore, this systematic review aimed to summarize significant predictors for LEV pharmacokinetics as well as the need for dosage adjustments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a systematic search for population pharmacokinetic studies of LEV conducted using a nonlinear-mixed effect approach from PubMed, Scopus, CINAHL Complete, and Science Direct databases from their inception to March 2020. Information on study design, model methodologies, significant covariate-parameter relationships, and model evaluation was extracted. The quality of the reported studies was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 16 studies were included in this review. Only two studies were conducted with a two-compartment model, while the rest were performed with a one-compartment structure. Bodyweight and creatinine clearance were the two most frequently identified covariates on LEV clearance (CLLEV). Additionally, postmenstrual age (PMA) or postnatal age (PNA) were significant predictors for CLLEV in neonates. Only three studies externally validated the models. Two studies conducted pharmacodynamic models for LEV with relatively small sample size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Significant predictors for LEV pharmacokinetics are highlighted in this review. For future research, a population pharmacokinetic-pharmacodynamic model using a larger sample size should be conducted. From a clinical perspective, the published models should be externally evaluated before clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1574884716666210223110658","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T23:48:05Z","timestamp":1614124085000},"page":"122-134","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetics of Levetiracetam: A Systematic Review"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-8769","authenticated-orcid":true,"given":"Janthima","family":"Methaneethorn","sequence":"first","affiliation":[{"name":"Pharmacokinetic Research Unit, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan\nUniversity, Phitsanulok, Thailand"},{"name":"Center of Excellence for Environmental Health and Toxicology, Naresuan University,\nPhitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-4775","authenticated-orcid":true,"given":"Nattawut","family":"Leelakanok","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Burapha University,\nChonburi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021035s099,021505s038lbl.pdf"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fneur.2014.00011","volume":"5","author":"Deshpande L.S.","year":"2014","unstructured":"Deshpande L.S.; Delorenzo R.J.; Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol 2014,5,11","journal-title":"Front Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fneur.2013.00192","volume":"4","author":"Wright C.","year":"2013","unstructured":"Wright C.; Downing J.; Mungall D.; Khan O.; Williams A.; Fonkem E.; Garrett D.; Aceves J.; Kirmani B.; Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol 2013,4,192","journal-title":"Front Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fneur.2013.00121","volume":"4","author":"Dewolfe J.L.","year":"2013","unstructured":"Dewolfe J.L.; Szaflarski J.P.; Levetiracetam use in the critical care setting. Front Neurol 2013,4,121","journal-title":"Front Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"Patsalos P.N.","year":"2004","unstructured":"Patsalos P.N.; Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004,43(11),707-724","journal-title":"Clin Pharmacokinet"},{"key":"ref=6","author":"Murphy JE","year":"2011","unstructured":"Murphy JE; Clinical Pharmacokinetics: ASHP. 2011"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/j.1528-1167.2010.02519.x","volume":"51","author":"Depositario-Cabacar D.T.","year":"2010","unstructured":"Depositario-Cabacar D.T.; Peters J.M.; Pong A.W.; Roth J.; Rotenberg A.; Riviello J.J.; Takeoka M.; High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia 2010,51(7),1319-1322","journal-title":"Epilepsia"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.eplepsyres.2007.07.011","volume":"76","author":"Snoeck E.","year":"2007","unstructured":"Snoeck E.; Jacqmin P.; Sargentini-Maier M.L.; Stockis A.; Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res 2007,76(2-3),140-147","journal-title":"Epilepsy Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"S031","DOI":"10.4103\/0976-3147.196445","volume":"7","author":"Gupta V","year":"2016","unstructured":"Gupta V; Gupta K; Singh G; Kaushal S; An analytical study to correlate serum levels of levetiracetam with clinical course in patients with epilepsy. Journal of neurosciences in rural practice 2016,7(1),S031-6","journal-title":"Journal of neurosciences in rural practice"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"Methaneethorn J.","year":"2018","unstructured":"Methaneethorn J.; A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol 2018,84(5),816-834","journal-title":"Br J Clin Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13318-017-0421-2","volume":"43","author":"Methaneethorn J.","year":"2018","unstructured":"Methaneethorn J.; Population pharmacokinetic analyses of lithium: a systematic review. Eur J Drug Metab Pharmacokinet 2018,43(1),25-34","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2165\/00003088-200746060-00004","volume":"46","author":"Pigeolet E.","year":"2007","unstructured":"Pigeolet E.; Jacqmin P.; Sargentini-Maier M.L.; Stockis A.; Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet 2007,46(6),503-512","journal-title":"Clin Pharmacokinet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00003088-200847050-00004","volume":"47","author":"Toublanc N.","year":"2008","unstructured":"Toublanc N.; Sargentini-Maier M.L.; Lacroix B.; Jacqmin P.; Stockis A.; Toublanc N.; Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet 2008,47(5),333-341","journal-title":"Clin Pharmacokinet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/j.1528-1167.2008.01974.x","volume":"50","author":"Chhun S.","year":"2009","unstructured":"Chhun S.; Jullien V.; Rey E.; Dulac O.; Chiron C.; Pons G.; Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 2009,50(5),1150-1157","journal-title":"Epilepsia"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/pr.2012.51","volume":"72","author":"Sharpe C.M.","year":"2012","unstructured":"Sharpe C.M.; Capparelli E.V.; Mower A.; Farrell M.J.; Soldin S.J.; Haas R.H.; A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res 2012,72(1),43-49","journal-title":"Pediatr Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/aps.2012.57","volume":"33","author":"Wang Y.H.","year":"2012","unstructured":"Wang Y.H.; Wang L.; Lu W.; Shang D.W.; Wei M.J.; Wu Y.; Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. Acta Pharmacol Sin 2012,33(6),845-851","journal-title":"Acta Pharmacol Sin"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2133\/dmpk.DMPK-13-RG-045","volume":"29","author":"Toublanc N.","year":"2014","unstructured":"Toublanc N.; Lacroix B.D.; Yamamoto J.; Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities. Drug Metab Pharmacokinet 2014,29(1),61-68","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/FTD.0000000000000291","volume":"38","author":"Ito S.","year":"2016","unstructured":"Ito S.; Yano I.; Hashi S.; Tsuda M.; Sugimoto M.; Yonezawa A.; Ikeda A.; Matsubara K.; Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data. Ther Drug Monit 2016,38(3),371-378","journal-title":"Ther Drug Monit"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eplepsyres.2017.02.011","volume":"132","author":"Rhee S.J.","year":"2017","unstructured":"Rhee S.J.; Shin J-W.; Lee S.; Moon J.; Kim T-J.; Jung K-Y.; Park K.I.; Lee S.T.; Jung K.H.; Yu K.S.; Jang I.J.; Chu K.; Lee S.K.; Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Epilepsy Res 2017,132,8-14","journal-title":"Epilepsy Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3345\/kjp.2017.60.2.50","volume":"60","author":"Shin J.W.","year":"2017","unstructured":"Shin J.W.; Jung Y.S.; Park K.; Lee S.M.; Eun H.S.; Park M.S.; Park K.I.; Namgung R.; Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. Korean J Pediatr 2017,60(2),50-54","journal-title":"Korean J Pediatr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5414\/CP203058","volume":"56","author":"Jung Y.S.","year":"2018","unstructured":"Jung Y.S.; Lee S.M.; Park M.S.; Park K.; Population pharmacokinetic model of levetiracetam in Korean neonates with seizures\u2029. Int J Clin Pharmacol Ther 2018,56(5),217-223","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/jcph.1282","volume":"58","author":"Kim M.J.","year":"2018","unstructured":"Kim M.J.; Yum M.S.; Yeh H.R.; Ko T.S.; Lim H.S.; Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy. J Clin Pharmacol 2018,58(12),1586-1596","journal-title":"J Clin Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/jcpt.12658","volume":"43","author":"Lima-Rogel V.","year":"2018","unstructured":"Lima-Rogel V.; L\u00f3pez-L\u00f3pez E.J.; Medell\u00edn-Garibay S.E.; G\u00f3mez-Ruiz L.M.; Romero-M\u00e9ndez C.; Mil\u00e1n-Segovia R.C.; Romano-Moreno S.; Population pharmacokinetics of levetiracetam in neonates with seizures. J Clin Pharm Ther 2018,43(3),422-429","journal-title":"J Clin Pharm Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.yebeh.2018.08.026","volume":"88","author":"Perrenoud M.","year":"2018","unstructured":"Perrenoud M.; Andr\u00e9 P.; Buclin T.; Decosterd L.A.; Rossetti A.O.; Novy J.; Levetiracetam circulating concentrations and response in status epilepticus. Epilepsy Behav 2018,88,61-65","journal-title":"Epilepsy Behav"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.xphs.2020.02.018","volume":"109","author":"Hern\u00e1ndez-Mitre M.P.","year":"2020","unstructured":"Hern\u00e1ndez-Mitre M.P.; Medell\u00edn-Garibay S.E.; Rodr\u00edguez-Leyva I.; Rodr\u00edguez-Pinal C.J.; Zaraz\u00faa S.; Jung-Cook H.H.; Roberts J.A.; Romano-Moreno S.; Mil\u00e1n-Segovia R.D.C.; Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. J Pharm Sci 2020,109(6),2070-2078","journal-title":"J Pharm Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00498254.2020.1746981","author":"Karatza E","year":"2020","unstructured":"Karatza E; Markantonis SL; Savvidou A; Verentzioti A; Siatouni A; Alexoudi A; Pharmacokinetic and Pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. Xenobiotica; the fate of foreign compounds in biological systems 2020,1-28","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","volume":"46","author":"Brendel K.","year":"2007","unstructured":"Brendel K.; Dartois C.; Comets E.; Lemenuel-Diot A.; Laveille C.; Tranchand B.; Girard P.; Laffont C.M.; Mentr\u00e9 F.; Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007,46(3),221-234","journal-title":"Clin Pharmacokinet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"Kanji S.","year":"2015","unstructured":"Kanji S.; Hayes M.; Ling A.; Shamseer L.; Chant C.; Edwards D.J.; Edwards S.; Ensom M.H.; Foster D.R.; Hardy B.; Kiser T.H.; la Porte C.; Roberts J.A.; Shulman R.; Walker S.; Zelenitsky S.; Moher D.; Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet 2015,54(7),783-795","journal-title":"Clin Pharmacokinet"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"Dartois C.","year":"2007","unstructured":"Dartois C.; Brendel K.; Comets E.; Laffont C.M.; Laveille C.; Tranchand B.; Mentr\u00e9 F.; Lemenuel-Diot A.; Girard P.; Overview of model-building strategies in population PK\/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 2007,64(5),603-612","journal-title":"Br J Clin Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/bcp.14272","volume":"86","author":"Abdel Jalil M.H.","year":"2020","unstructured":"Abdel Jalil M.H.; Abdullah N.; Alsous M.M.; Saleh M.; Abu-Hammour K.; A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. Br J Clin Pharmacol 2020,86(7),1267-1280","journal-title":"Br J Clin Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jpeds.2011.03.057","volume":"159","author":"Merhar S.L.","year":"2011","unstructured":"Merhar S.L.; Schibler K.R.; Sherwin C.M.; Meinzen-Derr J.; Shi J.; Balmakund T.; Vinks A.A.; Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr 2011,159(1),152-154.e3","journal-title":"J Pediatr"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.eplepsyres.2006.11.006","volume":"73","author":"Snoeck E.","year":"2007","unstructured":"Snoeck E.; Stockis A.; Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res 2007,73(3),284-291","journal-title":"Epilepsy Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/FTD.0000000000000158","volume":"37","author":"Naik G.S.","year":"2015","unstructured":"Naik G.S.; Kodagali R.; Mathew B.S.; Thomas M.; Prabha R.; Mathew V.; Fleming D.H.; Therapeutic Drug Monitoring of Levetiracetam and Lamotrigine: Is There a Need? Ther Drug Monit 2015,37(4),437-444","journal-title":"Ther Drug Monit"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"149s","DOI":"10.18433\/jpps30081","volume":"21","author":"Jarvie D.","year":"2018","unstructured":"Jarvie D.; Mahmoud S.H.; Therapeutic drug monitoring of levetiracetam in select populations. J Pharm Pharm Sci 2018,21(1s),149s-176s","journal-title":"J Pharm Pharm Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2125.2006.02782.x","volume":"63","author":"Zhao Q.","year":"2007","unstructured":"Zhao Q.; Jiang J.; Li X.; Lu Z.S.; Hu P.; Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Clin Pharmacol 2007,63(5),614-617","journal-title":"Br J Clin Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1528-1167.2007.01090.x","volume":"48","author":"Glauser T.A.","year":"2007","unstructured":"Glauser T.A.; Mitchell W.G.; Weinstock A.; Bebin M.; Chen D.; Coupez R.; Stockis A.; Lu Z.S.; Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007,48(6),1117-1122","journal-title":"Epilepsia"},{"key":"ref=37","first-page":"548","volume":"6","author":"Stewart C.F.","year":"1987","unstructured":"Stewart C.F.; Hampton E.M.; Effect of maturation on drug disposition in pediatric patients. Clin Pharm 1987,6(7),548-564","journal-title":"Clin Pharm"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1517\/17425255.1.3.447","volume":"1","author":"Strolin Benedetti M.","year":"2005","unstructured":"Strolin Benedetti M.; Whomsley R.; Baltes E.L.; Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005,1(3),447-471","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-19.4.262","volume":"19","author":"Lu H.","year":"2014","unstructured":"Lu H.; Rosenbaum S.; Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther 2014,19(4),262-276","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"Batchelor H.K.","year":"2015","unstructured":"Batchelor H.K.; Marriott J.F.; Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol 2015,79(3),395-404","journal-title":"Br J Clin Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.2042-7158.1998.tb06190.x","volume":"50","author":"Mahmood I.","year":"1998","unstructured":"Mahmood I.; Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions. J Pharm Pharmacol 1998,50(5),493-499","journal-title":"J Pharm Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","volume":"61","author":"Mahmood I.","year":"2006","unstructured":"Mahmood I.; Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006,61(5),545-557","journal-title":"Br J Clin Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"Holford N.H.","year":"1996","unstructured":"Holford N.H.; A size standard for pharmacokinetics. Clin Pharmacokinet 1996,30(5),329-332","journal-title":"Clin Pharmacokinet"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"Patsalos P.N.","year":"2008","unstructured":"Patsalos P.N.; Berry D.J.; Bourgeois B.F.; Cloyd J.C.; Glauser T.A.; Johannessen S.I.; Leppik I.E.; Tomson T.; Perucca E.; Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008,49(7),1239-1276","journal-title":"Epilepsia"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","volume":"85","author":"Patsalos P.N.","year":"2000","unstructured":"Patsalos P.N.; Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000,85(2),77-85","journal-title":"Pharmacol Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1046\/j.1528-1157.2003.25302.x","volume":"44","author":"Coupez R.","year":"2003","unstructured":"Coupez R.; Nicolas J.M.; Browne T.R.; Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 2003,44(2),171-178","journal-title":"Epilepsia"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","volume":"59","author":"Strolin Benedetti M.","year":"2003","unstructured":"Strolin Benedetti M.; Whomsley R.; Nicolas J-M.; Young C.; Baltes E.; Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol 2003,59(8-9),621-630","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1742-7843.2007.00061.x","volume":"100","author":"Gunes A.","year":"2007","unstructured":"Gunes A.; Bilir E.; Zengil H.; Babaoglu M.O.; Bozkurt A.; Yasar U.; Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol 2007,100(6),383-386","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","volume":"65","author":"Ethell B.T.","year":"2003","unstructured":"Ethell B.T.; Anderson G.D.; Burchell B.; The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 2003,65(9),1441-1449","journal-title":"Biochem Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1365-2125.1990.tb03698.x","volume":"29","author":"Robbins D.K.","year":"1990","unstructured":"Robbins D.K.; Wedlund P.J.; Kuhn R.; Baumann R.J.; Levy R.H.; Chang S.L.; Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 1990,29(6),759-762","journal-title":"Br J Clin Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/00007691-200312000-00007","volume":"25","author":"May T.W.","year":"2003","unstructured":"May T.W.; Rambeck B.; J\u00fcrgens U.; Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003,25(6),690-699","journal-title":"Ther Drug Monit"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00007691-200408000-00006","volume":"26","author":"Contin M.","year":"2004","unstructured":"Contin M.; Albani F.; Riva R.; Baruzzi A.; Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 2004,26(4),375-379","journal-title":"Ther Drug Monit"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0920-1211(02)00250-4","volume":"53","author":"Perucca E.","year":"2003","unstructured":"Perucca E.; Gidal B.E.; Balt\u00e8s E.; Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 2003,53(1-2),47-56","journal-title":"Epilepsy Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","volume":"98","author":"Anderson B.J.","year":"2013","unstructured":"Anderson B.J.; Holford N.H.; Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 2013,98(9),737-744","journal-title":"Arch Dis Child"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574884716666210223110658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/191728\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574884716666210223110658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T11:08:59Z","timestamp":1663585739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/191728\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574884716666210223110658","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}